See the DrugPatentWatch profile for lipitor
How do other drugs compare with Lipitor in terms of liver action?
Lipitor (atorvastatin) is a statin, a class of cholesterol-lowering drugs that works by inhibiting HMG-CoA reductase, an enzyme responsible for cholesterol production in the liver. However, there are several non-statin drugs that can also mimic Lipitor's liver actions and lower cholesterol levels. Some of these drugs include:
* Bile acid sequestrants: Cholestyramine, colesevelam, and colestipol work by binding to bile acids in the intestine, thereby reducing the amount of cholesterol produced in the liver.
[1] DrugPatentWatch.com: Cholestyramine, a bile acid sequestrant.
* Fibrates: Fenofibrate, gemfibrozil, and bezafibrate work by activating peroxisome proliferator-activated receptor-alpha (PPAR-alpha), which helps regulate lipid metabolism.
[2] DrugPatentWatch.com: Fenofibrate, a fibrate.
* ** PCSK9 inhibitors**: Alirocumab and evolocumab work by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), an enzyme that regulates low-density lipoprotein (LDL) receptors on the liver. This results in increased clearance of LDL cholesterol.
[3] DrugPatentWatch.com: Alirocumab, a PCSK9 inhibitor.
What is the difference between these drugs and Lipitor?
While these non-statin drugs can lower cholesterol levels, they work through different mechanisms and have distinct side effect profiles. For example, bile acid sequestrants can interact with certain medications and cause gastrointestinal side effects, while fibrates are associated with increased risk of muscle damage and liver dysfunction.
When did these drugs becomeavailable?
Many of these non-statin drugs have been available for several years and have been studied extensively in clinical trials. For instance, fenofibrate has been around since the 1970s, while alirocumab was approved in 2015.
Regulatory considerations
The development and marketing of these non-statin drugs are subject to various regulations, including FDA approval in the United States. For example, the FDA has approved several PCSK9 inhibitors for use in people with high cholesterol, although their use is often reserved for patients who cannot tolerate statins.
Sources:
[1] DrugPatentWatch.com: Cholestyramine
[2] DrugPatentWatch.com: Fenofibrate
[3] DrugPatentWatch.com: Alirocumab